



|  |   |    |    |                              |                                   |
|--|---|----|----|------------------------------|-----------------------------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |   |    |    | APPLICATION NO.: 10/817,165  | ATTY. DOCKET NO.: C1039.70048US02 |
|  |   |    |    | FILING DATE: April 2, 2004   | CONFIRMATION NO.: 1597            |
|  |   |    |    | APPLICANT: Krieg et al.      |                                   |
|  |   |    |    | GROUP ART UNIT: 1645         |                                   |
| Sheet  | 1 | of | 16 | EXAMINER: Nita M. Minnifield |                                   |

### U.S. PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | U.S. Patent Document |           | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|-----------------------|----------|----------------------|-----------|---|---|
|                       |          | Number               | Kind Code |   |   |
|                       | A1       | 5,112,605            |           | Jardieu et al.                                  | 05-12-1992  |
|                       | A2       | 5,498,410            |           | Gleich  | 03-12-1996  |
|                       | A3       | 5,663,153            |           | Hutcherson et al.                               | 09-02-1997  |
|                       | A4       | 5,679,647            |           | Carson et al.                                   | 10-21-1997  |
|                       | A5       | 5,681,555            |           | Gleich  | 10-28-1997  |
|                       | A6       | 5,723,335            |           | Hutcherson et al.                               | 03-03-1998  |
|                       | A7       | 5,726,160            |           | McMichael                                       | 03-10-1998  |
|                       | A8       | 5,804,566            |           | Carson et al.                                   | 09-08-1998  |
|                       | A9       | 5,849,719            |           | Carson et al.                                   | 12-15-1998  |
|                       | A10      | 5,908,620            |           | Tu et al.                                       | 06-01-1999  |
|                       | A11      | 5,955,059            |           | Gilchrest et al.                                | 09-21-1999  |
|                       | A12      | 5,955,442            |           | McMichael                                       | 09-21-1999  |
|                       | A13      | 5,994,315            |           | Nyce et al.                                     | 11-30-1999  |
|                       | A14      | 6,025,339            |           | Nyce et al.                                     | 02-15-2000  |
|                       | A15      | 6,040,296            |           | Nyce et al.                                     | 03-21-2000  |
|                       | A16      | 6,096,721            |           | McMichael                                       | 08-01-2000  |
|                       | A17      | 6,100,244            |           | McMichael                                       | 08-08-2000  |
|                       | A18      | 6,174,872            | B1        | Carson et al.                                   | 01-16-2001  |
|                       | A19      | 6,194,388            | B1        | Krieg et al.                                    | 02-27-2001  |
|                       | A20      | 6,207,646            | B1        | Krieg et al.                                    | 03-27-2001  |
|                       | A21      | 6,214,806            | B1        | Krieg et al                                     | 04-10-2001  |
|                       | A22      | 6,218,371            | B1        | Krieg et al.                                    | 04-17-2001  |
|                       | A23      | 6,221,882            | B1        | Macfarlane                                      | 04-24-2001  |
|                       | A24      | 6,225,292            | B1        | Raz et al.                                      | 05-01-2001  |
|                       | A25      | 6,239,116            | B1        | Krieg et al.                                    | 05-29-2001  |
|                       | A26      | 6,339,068            | B1        | Krieg et al.                                    | 01-15-2002  |
|                       | A27      | 6,399,630            | B1        | Macfarlane                                      | 06-04-2002  |
|                       | A28      | 6,406,705            | B1        | Davis et al.                                    | 06-18-2002  |
|                       | A29      | 6,426,336            | B1        | Carson et al.                                   | 07-30-2002  |
|                       | A30      | 6,429,199            | B1        | Krieg et al.                                    | 08-06-2002  |
|                       | A31      | 6,479,504            | B1        | Macfarlane et al.                               | 11-12-2002  |
|                       | A32      | 6,498,148            | B1        | Raz   | 12-24-2002  |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |   |    |    |                             |                                   |
|---|---|----|----|-----------------------------|-----------------------------------|
| <b>FORM PTO-1449/A and B (modified PTO/SB/08)</b><br><b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b> |   |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
|   |   |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |   |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 2 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|  |     |              |    |                   |            |
|--|-----|--------------|----|-------------------|------------|
|  | A33 | 6,514,948    | B1 | Raz et al.        | 02-04-2003 |
|  | A34 | 6,521,637    | B2 | Macfarlane        | 02-18-2003 |
|  | A35 | 6,562,798    | B1 | Schwartz          | 05-13-2003 |
|  | A36 | 6,589,940    | B1 | Raz et al.        | 07-08-2003 |
|  | A37 | 6,610,661    | B1 | Carson et al.     | 08-26-2003 |
|  | A38 | 6,653,292    | B1 | Krieg et al.      | 11-25-2003 |
|  | A39 | 6,727,230    | B1 | Hutcherson et al. | 04-27-2004 |
|  | A40 | 6,787,524    | B2 | Chang et al.      | 09-07-2004 |
|  | A41 | 6,821,957    | B1 | Krieg et al.      | 11-23-2004 |
|  | A42 | 6,943,240    | B2 | Bauer et al.      | 09-13-2005 |
|  | A43 | 6,949,520    | B1 | Hartmann et al.   | 09-27-2005 |
|  | A44 | 6,951,845    | B2 | Carson et al.     | 10-04-2005 |
|  | A45 | 7,001,890    | B1 | Wagner et al.     | 02-21-2006 |
|  | A46 | 7,223,741    | B2 | Krieg             | 05-29-2007 |
|  | A47 | 2001-0044416 | A1 | McCluskie et al.  | 11-22-2001 |
|  | A48 | 2002-0064515 | A1 | Krieg et al.      | 05-30-2002 |
|  | A49 | 2002-0086839 | A1 | Raz et al.        | 07-04-2002 |
|  | A50 | 2002-0091097 | A1 | Bratzler et al.   | 07-11-2002 |
|  | A51 | 2002-0102255 | A1 | Chang             | 08-01-2002 |
|  | A52 | 2002-0156033 | A1 | Bratzler et al.   | 10-24-2002 |
|  | A53 | 2002-0164341 | A1 | Davis et al.      | 11-07-2002 |
|  | A54 | 2002-0165178 | A1 | Schetter et al    | 11-07-2002 |
|  | A55 | 2002-0198165 | A1 | Bratzler et al.   | 12-26-2002 |
|  | A56 | 2002-0164341 | A1 | Davis et al.      | 11-07-2002 |
|  | A57 | 2003-0026782 | A1 | Krieg             | 02-02-2003 |
|  | A58 | 2003-0026801 | A1 | Weiner et al.     | 02-06-2003 |
|  | A59 | 2003-0027782 | A1 | Carson et al.     | 02-06-2003 |
|  | A60 | 2003-0049266 | A1 | Fearon et al.     | 03-13-2003 |
|  | A61 | 2003-0050261 | A1 | Krieg et al.      | 03-13-2003 |
|  | A62 | 2003-0050263 | A1 | Krieg et al.      | 03-13-2003 |
|  | A63 | 2003-0050268 | A1 | Krieg et al.      | 03-13-2003 |
|  | A64 | 2003-0055014 | A1 | Bratzler          | 03-20-2003 |
|  | A65 | 2003-0064064 | A1 | Dina et al.       | 04-03-2003 |
|  | A66 | 2003-0078223 | A1 | Raz et al.        | 04-24-2003 |
|  | A67 | 2003-0091599 | A1 | Davis et al.      | 05-15-2003 |
|  | A68 | 2003-0092663 | A1 | Raz et al.        | 05-15-2003 |
|  | A69 | 2003-0100527 | A1 | Krieg et al.      | 05-29-2003 |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|  |   |                             |                                   |                      |                              |
|--|---|-----------------------------|-----------------------------------|----------------------|------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)<br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |   | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |                      |                              |
|  |   | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |                      |                              |
|  |   | APPLICANT: Krieg et al.     |                                   |                      |                              |
| Sheet  | 3 | of                          | 16                                | GROUP ART UNIT: 1645 | EXAMINER: Nita M. Minnifield |

|  |      |              |    |                 |            |
|--|------|--------------|----|-----------------|------------|
|  | A70  | 2003-0119773 | A1 | Raz et al.      | 06-26-2003 |
|  | A71  | 2003-0139364 | A1 | Krieg et al.    | 07-24-2003 |
|  | A72  | 2003-0148316 | A1 | Lipford et al.  | 08-07-2003 |
|  | A73  | 2003-0148976 | A1 | Krieg et al.    | 08-07-2003 |
|  | A74  | 2003-0166001 | A1 | Lipford         | 09-04-2003 |
|  | A75  | 2003-0181406 | A1 | Schetter et al. | 09-25-2003 |
|  | A76  | 2003-0191079 | A1 | Krieg et al.    | 10-09-2003 |
|  | A77  | 2003-0212026 | A1 | Krieg et al.    | 11-13-2003 |
|  | A78  | 2003-0224010 | A1 | Davis et al.    | 12-04-2003 |
|  | A79  | 2003-0232074 | A1 | Lipford et al.  | 12-18-2003 |
|  | A80  | 2003-0232780 | A1 | Carson et al.   | 12-18-2003 |
|  | A81  | 2003-0232856 | A1 | Macfarlane      | 12-18-2003 |
|  | A82  | 2004-0006010 | A1 | Carson et al.   | 01-08-2004 |
|  | A83  | 2004-0006034 | A1 | Raz et al.      | 01-08-2004 |
|  | A84  | 2004-0009949 | A1 | Krieg           | 01-15-2004 |
|  | A85  | 2004-0030118 | A1 | Wagner et al.   | 02-12-2004 |
|  | A86  | 2004-0053880 | A1 | Krieg           | 03-18-2004 |
|  | A87  | 2004-0067902 | A9 | Bratzler et al. | 04-08-2004 |
|  | A88  | 2004-0067905 | A1 | Krieg           | 04-08-2004 |
|  | A89  | 2004-0087534 | A1 | Krieg et al.    | 05-06-2004 |
|  | A90  | 2004-0087538 | A1 | Krieg et al.    | 05-06-2004 |
|  | A91  | 2004-0092468 | A1 | Schwartz et al. | 05-13-2004 |
|  | A92  | 2004-0092472 | A1 | Krieg           | 05-13-2004 |
|  | A93  | 2004-0106568 | A1 | Krieg et al.    | 06-03-2004 |
|  | A94  | 2004-0131628 | A1 | Bratzler et al. | 07-08-2004 |
|  | A95  | 2004-0132685 | A1 | Krieg et al.    | 07-08-2004 |
|  | A96  | 2004-0142469 | A1 | Krieg et al.    | 07-22-2004 |
|  | A97  | 2004-0143112 | A1 | Krieg et al.    | 07-22-2004 |
|  | A98  | 2004-0147468 | A1 | Krieg et al.    | 07-29-2004 |
|  | A99  | 2004-0152649 | A1 | Krieg           | 08-05-2004 |
|  | A100 | 2004-0152656 | A1 | Krieg et al.    | 08-05-2004 |
|  | A101 | 2004-0152657 | A1 | Krieg et al.    | 08-05-2004 |
|  | A102 | 2004-0162258 | A1 | Krieg et al.    | 08-19-2004 |
|  | A103 | 2004-0162262 | A1 | Krieg et al.    | 08-19-2004 |
|  | A104 | 2004-0167089 | A1 | Krieg et al.    | 08-26-2004 |
|  | A105 | 2004-0171150 | A1 | Krieg et al.    | 09-02-2004 |
|  | A106 | 2004-0171571 | A1 | Krieg et al.    | 09-02-2004 |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|  |   |    |    |                             |                                   |
|--|---|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)<br><br>INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT |   |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
|  |   |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|  |   |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet  | 4 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|  |      |              |    |                   |            |
|--|------|--------------|----|-------------------|------------|
|  | A107 | 2004-0181045 | A1 | Krieg et al.      | 09-16-2004 |
|  | A108 | 2004-0198680 | A1 | Krieg             | 10-07-2004 |
|  | A109 | 2004-0198688 | A1 | Krieg et al.      | 10-07-2004 |
|  | A110 | 2004-0229835 | A1 | Krieg et al.      | 11-18-2004 |
|  | A111 | 2004-0234512 | A1 | Wagner et al.     | 11-25-2004 |
|  | A112 | 2004-0235770 | A1 | Davis et al.      | 11-25-2004 |
|  | A113 | 2004-0235774 | A1 | Bratzler et al.   | 11-25-2004 |
|  | A114 | 2004-0235777 | A1 | Wagner et al.     | 11-25-2004 |
|  | A115 | 2004-0235778 | A1 | Wagner et al.     | 11-25-2004 |
|  | A116 | 2004-0248837 | A1 | Raz et al.        | 12-09-2004 |
|  | A117 | 2004-0266719 | A1 | McCluskie et al.  | 12-30-2004 |
|  | A118 | 2005-0004061 | A1 | Krieg et al.      | 01-06-2005 |
|  | A119 | 2005-0004062 | A1 | Krieg et al.      | 01-06-2005 |
|  | A120 | 2005-0009774 | A1 | Krieg et al.      | 01-13-2005 |
|  | A121 | 2005-0032734 | A1 | Davis et al.      | 02-10-2005 |
|  | A122 | 2005-0032736 | A1 | Krieg et al.      | 02-10-2005 |
|  | A123 | 2005-0037403 | A1 | Krieg et al.      | 02-17-2005 |
|  | A124 | 2005-0037985 | A1 | Krieg et al.      | 02-17-2005 |
|  | A125 | 2005-0043529 | A1 | Davis et al.      | 02-24-2005 |
|  | A126 | 2005-0049215 | A1 | Krieg et al.      | 03-03-2005 |
|  | A127 | 2005-0049216 | A1 | Krieg et al.      | 03-03-2005 |
|  | A128 | 2005-0054601 | A1 | Wagner et al.     | 03-10-2005 |
|  | A129 | 2005-0054602 | A1 | Krieg et al.      | 03-10-2005 |
|  | A130 | 2005-0059619 | A1 | Krieg et al.      | 03-17-2005 |
|  | A131 | 2005-0059625 | A1 | Krieg et al.      | 03-17-2005 |
|  | A132 | 2005-0070491 | A1 | Krieg et al.      | 03-31-2005 |
|  | A133 | 2005-0075302 | A1 | Hutcherson et al. | 04-07-2005 |
|  | A134 | 2005-0100983 | A1 | Bauer et al.      | 05-12-2005 |
|  | A135 | 2005-0101554 | A1 | Krieg et al.      | 05-12-2005 |
|  | A136 | 2005-0101557 | A1 | Krieg et al.      | 05-12-2005 |
|  | A137 | 2005-0119273 | A1 | Lipford et al.    | 06-02-2005 |
|  | A138 | 2005-0123523 | A1 | Krieg et al.      | 06-09-2005 |
|  | A139 | 2005-0130911 | A1 | Uhlmann et al.    | 06-16-2005 |
|  | A140 | 2005-0148537 | A1 | Krieg et al.      | 07-07-2005 |
|  | A141 | 2005-0169888 | A1 | Hartman et al.    | 08-04-2005 |
|  | A142 | 2005-0171047 | A1 | Krieg et al.      | 08-04-2005 |
|  | A143 | 2005-0181422 | A1 | Bauer et al.      | 08-18-2005 |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|  |  |  |  |                             |                                   |    |
|--|--|--|--|-----------------------------|-----------------------------------|----|
| FORM PTO-1449/A and B (modified PTO/SB/08)<br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |  |  |  | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |    |
|  |  |  |  | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |    |
|  |  |  |  | APPLICANT: Krieg et al.     |                                   |    |
|  |  |  |  | Sheet                       | 5                                 | of |

|  |      |              |    |                  |            |
|--|------|--------------|----|------------------|------------|
|  | A144 | 2005-0182017 | A1 | Krieg            | 08-18-2005 |
|  | A145 | 2005-0197314 | A1 | Krieg et al.     | 09-08-2005 |
|  | A146 | 2005-0215500 | A1 | Krieg et al.     | 09-29-2005 |
|  | A147 | 2005-0215501 | A1 | Lipford et al.   | 09-29-2005 |
|  | A148 | 2005-0233995 | A1 | Krieg et al.     | 10-20-2005 |
|  | A149 | 2005-0233999 | A1 | Krieg et al.     | 10-20-2005 |
|  | A150 | 2005-0239732 | A1 | Krieg et al.     | 10-27-2005 |
|  | A151 | 2005-0239733 | A1 | Jurk et al.      | 10-27-2005 |
|  | A152 | 2005-0239734 | A1 | Uhlmann et al.   | 10-27-2005 |
|  | A153 | 2005-0239736 | A1 | Krieg et al.     | 10-27-2005 |
|  | A154 | 2005-0244379 | A1 | Krieg et al.     | 11-03-2005 |
|  | A155 | 2005-0244380 | A1 | Krieg et al.     | 11-03-2005 |
|  | A156 | 2005-0245477 | A1 | Krieg et al.     | 11-03-2005 |
|  | A157 | 2005-0250726 | A1 | Krieg et al.     | 11-10-2005 |
|  | A158 | 2005-0256073 | A1 | Lipford et al.   | 11-17-2005 |
|  | A159 | 2005-0267064 | A1 | Krieg et al.     | 12-01-2005 |
|  | A160 | 2005-0277604 | A1 | Krieg et al.     | 12-15-2005 |
|  | A161 | 2005-0277609 | A1 | Krieg et al.     | 12-15-2005 |
|  | A162 | 2006-0003955 | A1 | Krieg et al.     | 01-05-2006 |
|  | A163 | 2006-0003962 | A1 | Ahluwalia et al. | 01-05-2006 |
|  | A164 | 2006-0019916 | A1 | Krieg et al.     | 01-26-2006 |
|  | A165 | 2006-0019923 | A1 | Davis et al.     | 01-26-2006 |
|  | A166 | 2006-0058251 | A1 | Krieg et al.     | 03-16-2006 |
|  | A167 | 2006-0089326 | A1 | Krieg et al.     | 04-27-2006 |
|  | A168 | 2006-0094683 | A1 | Krieg et al.     | 05-04-2006 |
|  | A169 | 2006-0140875 | A1 | Krieg et al.     | 06-29-2006 |
|  | A170 | 2006-0154890 | A1 | Bratzler et al.  | 07-13-2006 |
|  | A171 | 2006-0172966 | A1 | Lipford et al.   | 08-03-2006 |
|  | A172 | 2006-0188913 | A1 | Krieg et al.     | 08-24-2006 |
|  | A173 | 2006-0211639 | A1 | Bratzler et al.  | 09-21-2006 |
|  | A174 | 2006-0211644 | A1 | Krieg et al.     | 09-21-2006 |
|  | A175 | 2006-0229271 | A1 | Krieg et al.     | 10-12-2006 |
|  | A176 | 2006-0241076 | A1 | Uhlmann et al.   | 10-26-2006 |
|  | A177 | 2006-0246035 | A1 | Ahluwalia et al. | 11-02-2006 |
|  | A178 | 2006-0286070 | A1 | Hartmann et al.  | 12-21-2006 |
|  | A179 | 2006-0287263 | A1 | Davis et al.     | 12-21-2006 |
|  | A180 | 2007-0009482 | A1 | Krieg et al.     | 01-11-2007 |

|           |                  |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |   |    |    |                             |                                   |
|---|---|----|----|-----------------------------|-----------------------------------|
| <b>FORM PTO-1449/A and B (modified PTO/SB/08)</b><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> |   |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
|   |   |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |   |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 6 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|  |      |              |    |                 |            |
|--|------|--------------|----|-----------------|------------|
|  | A181 | 2007-0010470 | A1 | Krieg et al.    | 01-11-2007 |
|  | A182 | 2007-0037767 | A1 | Bratzler et al. | 02-15-2007 |
|  | A183 | 2007-0065467 | A1 | Krieg et al.    | 03-22-2007 |
|  | A184 | 2007-0066553 | A1 | Krieg et al.    | 03-22-2007 |
|  | A185 | 2007-0066554 | A1 | Krieg et al.    | 03-22-2007 |
|  | A186 | 2007-0078104 | A1 | Krieg et al.    | 04-05-2007 |
|  | A187 | 2007-0129320 | A9 | Davis et al.    | 06-07-2007 |
|  | A188 | 2007-0142315 | A1 | Forsbach et al. | 06-21-2007 |
|  | A189 | 2007-0184465 | A1 | Wagner et al.   | 08-09-2007 |
|  | A190 | 2007-0202128 | A1 | Krieg et al.    | 08-30-2007 |

#### FOREIGN PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | Foreign Patent Document |             |           | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|-----------------------|----------|-------------------------|-------------|-----------|---|--|-------------------|
|                       |          | Office/ Country         | Number      | Kind Code |   |  |                   |
| *                     | B1       | EP                      | 0 468 520   | A2        | Mitsui Toatsu Chemicals, Inc.                   | 01-29-1992                                       |                   |
|                       | B2       | WO                      | 96/32138    | A1        | Milkhaus Laboratory                             | 10-17-1996                                       |                   |
|                       | B3       | WO                      | 96/40162    | A1        | East Carolina University                        | 12-19-1996                                       |                   |
|                       | B4       | WO                      | 98/55495    | A2        | Dynavax Technologies Corporation                | 12-10-1998                                       |                   |
|                       | B5       | WO                      | 99/11275    | A2        | The Regents of the University of California     | 03-11-1999                                       |                   |
| *                     | B6       | WO                      | 99/56755    | A1        | University of Iowa Research Foundation          | 11-11-1999                                       |                   |
| *                     | B7       | WO                      | 00/06588    | A1        | University of Iowa Research Foundation          | 02-10-2000                                       |                   |
| *                     | B8       | WO                      | 00/14217    | A2        | CPG Immunopharmaceuticals GMBH                  | 03-16-2000                                       |                   |
| *                     | B9       | WO                      | 00/54803    | A2        | Panacea Pharmaceuticals, LLC.                   | 09-21-2000                                       |                   |
| *                     | B10      | WO                      | 00/67023    | A1        | CPG Immunopharmaceuticals GMBH                  | 11-09-2000                                       |                   |
|                       | B11      | WO                      | 01/45750    | A1        | Regents of the University of California         | 06-28-2001                                       |                   |
| *                     | B12      | WO                      | 2004/007743 | A2        | Coley Pharmaceutical GMBH                       | 01-22-2004                                       |                   |
|                       | B13      | WO                      | 2004/026888 | A2        | Coley Pharmaceutical GMBH                       | 04-01-2004                                       |                   |
|                       | B14      | WO                      | 2004/094671 | A2        | Coley Pharmaceutical GMBH                       | 11-04-2004                                       |                   |
|                       | B15      | WO                      | 2006/080946 | A2        | Coley Pharmaceutical GMBH                       | 08-03-2006                                       |                   |
|                       | B16      | WO                      | 2007/031877 | A2        | Coley Pharmaceutical GMBH                       | 03-22-2007                                       |                   |
|                       | B17      | WO                      | 2007/038720 | A2        | Coley Pharmaceutical GMBH                       | 04-05-2007                                       |                   |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |   |    |    |                             |                                   |
|---|---|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)    |   |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT |   |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |   |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 7 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | Translation (Y/N) |
|-----------------------|---------|--|-------------------|
|                       | C1      | [No Author Listed] National Institute of Health, Publication Number 97-4051, July 1997.  |                   |
|                       | C2      | Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy".   |                   |
|                       | C3      | Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".   |                   |
|                       | C4      | ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. <i>J Interferon Cytokine Res.</i> 1997 Dec;17(12):781-8.  |                   |
| *                     | C5      | BALLAS et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.  |                   |
| *                     | C6      | BOGGS et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):461-71.  |                   |
|                       | C7      | BROIDE et al., DNA-Based immunization for asthma. <i>Int Arch Allergy Immunol.</i> 1999 Feb-Apr;118(2-4):453-6.  |                   |
|                       | C8      | BROIDE et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. <i>J Immunol.</i> 1998 Dec 15;161(12):7054-62.   |                   |
|                       | C9      | BROIDE et al., Modulation of asthmatic response by immunostimulatory DNA sequences. <i>Springer Semin Immunopathol.</i> 2000;22(1-2):117-24.   |                   |
| *                     | C10     | CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. <i>J Exp Med.</i> 1997 Nov 17;186(10):1621-2.  |                   |
|                       | C11     | CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. <i>Clin Immunol Immunopathol.</i> 1997 Aug;84(2):185-93.   |                   |
| *                     | C12     | CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med.</i> 1997 Nov 17;186(10):1623-31.  |                   |
|                       | C13     | COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. <i>J Clin Immunol.</i> 2004 Nov;24(6):693-701.   |                   |
|                       | C14     | COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. <i>Vaccine.</i> 2004 Aug 13;22(23-24):3136-43.   |                   |
| *                     | C15     | COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. <i>J Immunol.</i> 1996 Jun 15;156(12):4570-5.   |                   |
|                       | C16     | CRETICOS et al., Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. <i>J Allergy Clin Immunol.</i> 2002;109(4):741-3. |                   |
| *                     | C17     | DURHAM et al., Immunotherapy and allergic inflammation. <i>Clin Exp Allergy.</i> 1991 Jan;21 Suppl 1:206-10.   |                   |
|                       | C18     | FORNADLEY, Allergy immunotherapy. <i>Otolaryngol Clin North Am.</i> 1998 Feb;31(1):111-27. Abstract Only.  |                   |
|                       | C19     | HALPERIN et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. <i>Vaccine.</i> 2003 Jun 2;21(19-20):2461-7.                   |                   |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|  |   |    |    |                             |                                   |
|--|---|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |   |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
|  |   |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|  |   |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet  | 8 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |     |   |  |
|---|-----|---|--|
| * | C20 | HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol.</i> 1996 Jan 10;167(1):72-8.  |  |
|   | C21 | HOGG, The pathology of asthma. <i>APMIS.</i> 1997 Oct;105(10):735-45.   |  |
|   | C22 | HORNER et al., Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. <i>J Allergy Clin Immunol.</i> 2002 Nov;110(5):706-12. |  |
|   | C23 | HUSSAIN et al., CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders. <i>Curr Drug Targets Inflamm Allergy.</i> 2003 Sep;2(3):199-205.  |  |
|   | C24 | JAIN et al., CpG DNA and immunotherapy of allergic airway diseases. <i>Clin Exp Allergy.</i> 2003 Oct;33(10):1330-5.  |  |
|   | C25 | JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. <i>J Immunol.</i> 1998 Sep 15;161(6):3042-9.         |  |
| * | C26 | KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res.</i> 1992 Mar;83(3):244-7.   |  |
|   | C27 | KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from <i>Mycobacterium bovis</i> BCG complexed with poly-L-lysine and carboxymethylcellulose. <i>Jpn J Med Sci Biol.</i> 1990 Oct;43(5):171-82. |  |
|   | C28 | KAY et al., Allergy and allergic diseases. Second of two parts. <i>N Engl J Med.</i> 2001 Jan 11;344(2):109-13.   |  |
| * | C29 | KIMURA et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. <i>J Biochem (Tokyo).</i> 1994 Nov;116(5):991-4.   |  |
|   | C30 | KITAGAKI et al., Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. <i>Clin Exp Immunol.</i> 2006 Feb;143(2):249-59.  |  |
| * | C31 | KLINE et al., The American Federation for Clinical Research, Midwestern section and Eastern section annual meetings. 1996. Abstracts. <i>J Investig Med.</i> 1996 Sep;44(7): 380A.  |  |
| * | C32 | KLINE et al., Biomedicine '97. Medical research from bench to bedside. Washington, D.C., April 25-27, 1997. Abstracts. <i>J Investig Med.</i> 1997 Mar;45(3): 282A.   |  |
| * | C33 | KLINE et al., American Federation for Medical Research Midwestern Regional Meeting. Chicago, Illinois, September 25-27, 1997. Abstracts. <i>J Investig Med.</i> 1997 Sep;45(7): 298A.   |  |
|   | C34 | KLINE et al., CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. <i>J Allergy Clin Immunol.</i> 1999 Dec;104(6):1258-64.   |  |
|   | C35 | KLINE et al., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. <i>Am J Physiol Lung Cell Mol Physiol.</i> 2002 Jul;283(1):L170-9.   |  |
|   | C36 | KLINE et al., Effects of CpG DNA on Th1/Th2 balance in asthma. <i>Curr Top Microbiol Immunol.</i> 2000;247:211-25.  |  |
|   | C37 | KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol.</i> 1997 Apr 15;158(8):3635-9.  |  |
| * | C38 | KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci U S A.</i> 1996 Apr 2;93(7):2879-83.                                      |  |

|           |                  |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |   |    |    |                             |                                   |
|---|---|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)    |   |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT |   |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |   |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 9 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |     |  |  |
|---|-----|--|--|
|   | C39 | KOU et al., [Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma] Arerugi. 1994 Mar;43(3):482-91. Japanese. Abstract Only.  |  |
|   | C40 | KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 2000 Jul 25;48(3):303-5.   |  |
|   | C41 | KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 <sup>th</sup> National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl). |  |
| * | C42 | KRIEG et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):133-9.   |  |
| * | C43 | KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev. 1995 Winter;5(4):241.  |  |
| * | C44 | KRIEG et al., Leukocyte stimulation by oligodeoxynucleotides. In: Applied Antisense Oligonucleotide Technology. 1998:431-48.   |  |
| * | C45 | KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov;15(6):284-92.  |  |
| * | C46 | KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.  |  |
| * | C47 | KRIEG et al., The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan;6(1):23-7.   |  |
|   | C48 | KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.   |  |
|   | C49 | KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal <i>L. monocytogenes</i> challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116.                             |  |
|   | C50 | KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.   |  |
|   | C51 | KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.   |  |
|   | C52 | KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge. J Immunol. 1998 Sep 1;161(5):2428-34.  |  |
|   | C53 | KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3.   |  |
|   | C54 | KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.   |  |
|   | C55 | KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.                                       |  |
|   | C56 | KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 8;19(6):618-22.  |  |
|   | C57 | KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.  |  |
| * | C58 | KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res. 1992 Nov;83(11):1128-31.   |  |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |    |    |    |                             |                                   |
|---|----|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)    |    |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT |    |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |    |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 10 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |     |   |  |
|---|-----|---|--|
|   | C59 | KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. <i>Microbiol Immunol.</i> 1989;33(11):929-40.  |  |
|   | C60 | LECLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. <i>Cell Immunol.</i> 1997 Aug 1;179(2):97-106.  |  |
| * | C61 | LEIBSON et al., Role of gamma-interferon in antibody-producing responses. <i>Nature.</i> 1984 Jun 28-Jul 4;309(5971):799-801.   |  |
| * | C62 | LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol.</i> 1997 Sep;27(9):2340-4.   |  |
| * | C63 | LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. <i>Eur J Immunol.</i> 1997 Dec;27(12):3420-6.  |  |
|   | C64 | LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. <i>J Invest Med.</i> 1997 Sept;45(7):333A.   |  |
|   | C65 | LUKACS et al., Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. <i>Am J Respir Cell Mol Biol.</i> 1994 May;10(5):526-32.  |  |
|   | C66 | LUKACS et al., C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation. <i>J Leukoc Biol.</i> 1996 Nov;60(5):573-8.   |  |
|   | C67 | MARSHALL et al., Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. <i>J Allergy Clin Immunol.</i> 2001 Aug;108(2):191-7. |  |
|   | C68 | MCCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. <i>J Immunol.</i> 1998 Nov 1;161(9):4463-6.   |  |
| * | C69 | MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. <i>Cell Immunol.</i> 1993 Mar;147(1):148-57.   |  |
|   | C70 | MOSMANN et al., The expanding universe of T-cell subsets: Th1, Th2 and more. <i>Immunol Today.</i> 1996 Mar;17(3):138-46.   |  |
| * | C71 | NYCE et al., DNA antisense therapy for asthma in an animal model. <i>Nature.</i> 1997 Feb 20;385(6618):721-5.   |  |
| * | C72 | PISETSKY et al., The immunologic properties of DNA. <i>J Immunol.</i> 1996 Jan 15;156(2):421-3.   |  |
| * | C73 | PISETSKY, Immunologic consequences of nucleic acid therapy. <i>Antisense Res Dev.</i> 1995 Fall;5(3):219-25.  |  |
| * | C74 | PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. <i>Mol Biol Rep.</i> 1993 Oct;18(3):217-21.  |  |
|   | C75 | PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. <i>Immunol Res.</i> 1999;19(1):35-46.  |  |
| * | C76 | PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Sci.</i> 1994;54(2):101-7.  |  |
|   | C77 | RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615.  |  |
| * | C78 | RAZ et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci U S A.</i> 1996 May 14;93(10):5141-5.  |  |

EXAMINER:

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |    |    |    |                             |                                   |
|---|----|----|----|-----------------------------|-----------------------------------|
| <b>FORM PTO-1449/A and B (modified PTO/SB/08)</b><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> |    |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
|   |    |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |    |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 11 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |     |  |  |
|---|-----|--|--|
|   | C79 | RICCI et al., T cells, cytokines, IgE and allergic airways inflammation. <i>J Investig Allergol Clin Immunol.</i> 1994 Sep-Oct;4(5):214-20.  |  |
|   | C80 | ROBINSON et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. <i>N Engl J Med.</i> 1992 Jan 30;326(5):298-304.   |  |
| * | C81 | ROMAN et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med.</i> 1997 Aug;3(8):849-54.  |  |
|   | C82 | ROMAN et al., Gene immunization for allergic disorders. <i>Springer Semin Immunopathol.</i> 1997;19(2):223-32.   |  |
| * | C83 | SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. <i>Science.</i> 1996 Jul 19;273(5273):352-4.   |  |
| * | C84 | SCHWARTZ et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest.</i> 1997 Jul 1;100(1):68-73.   |  |
|   | C85 | SEREBRISKY et al., CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. <i>J Immunol.</i> 2000 Nov 15;165(10):5906-12.                               |  |
|   | C86 | SIEGRIST et al., Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. <i>Vaccine.</i> 2004 Dec 16;23(5):615-22.   |  |
|   | C87 | SIMONS et al., Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. <i>J Allergy Clin Immunol.</i> 2004 Jun;113(6):1144-51.   |  |
|   | C88 | SJÖLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. <i>Cell Immunol.</i> 1997 Apr 10;177(1):69-76.  |  |
|   | C89 | SPARWASSER et al., Bacterial DNA causes septic shock. <i>Nature.</i> 1997 Mar 27;386(6623):336-7.  |  |
| * | C90 | SPARWASSER et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol.</i> 1997 Jul;27(7):1671-9.   |  |
|   | C91 | SPEISER et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>J Clin Invest.</i> 2005 Mar;115(3):739-46.  |  |
|   | C92 | SPIEGELBERG et al., DNA-based approaches to the treatment of allergies. <i>Curr Opin Mol Ther.</i> 2002 Feb;4(1):64-71.  |  |
|   | C93 | STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. <i>Antisense Res Dev.</i> 1994 Summer;4(2):67-9.  |  |
|   | C94 | STEIN et al., Non-antisense effects of oligodeoxynucleotides. <i>Antisense Technology.</i> 1997; ch11: 241-64.   |  |
| * | C95 | TOKUNAGA et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res.</i> 1988 Jun;79(6):682-6.                         |  |
| * | C96 | TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol.</i> 1992;36(1):55-66. |  |
|   | C97 | VAN OJIK et al., Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. <i>Ann Oncol.</i> 2003;13:157. Abstract 579O.  |  |
|   | C98 | VAN UDEN et al., Immunostimulatory DNA and applications to allergic disease. <i>J Allergy Clin Immunol.</i> 1999 Nov;104(5):902-10.  |  |
|   | C99 | WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1998 Aug;8(4):351-6.   |  |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |    |    |    |                             |                                   |
|---|----|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)    |    |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT |    |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |    |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 12 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |      |   |     |
|---|------|---|-----|
|   | C100 | WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.                                  |     |
|   | C101 | WEISS et al., Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases. Curr Drug Targets Inflamm Allergy. 2005 Oct;4(5):585-97.  |     |
| * | C102 | YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol. 1994;38(10):831-6.      |     |
| * | C103 | YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 1992 Jun 15;148(12):4072-6. |     |
| * | C104 | YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese.                            |     |
| * | C105 | YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev. 1994 Summer;4(2):119-22.        |     |
| * | C106 | YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9.  |     |
|   | C107 | YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9): 1178-84. Japanese.  | Yes |
|   | C108 | YI et al. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998 Nov 1;161(9):4493-7.  |     |
| * | C109 | YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol. 1996 Dec 15;157(12):5394-402.  |     |
| * | C110 | YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol. 1996 Jan 15;156(2):558-64.  |     |
|   | C111 | YI et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 1998 Jun 15;160(12):5898-906.  |     |
|   | C112 | ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.   |     |
| * | C113 | Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.   |     |
| * | C114 | Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.   |     |
| * | C115 | Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.  |     |
| * | C116 | Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.  |     |
| * | C117 | Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.                                     |     |

|           |                  |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|  |  |  |  |                             |                                   |
|--|--|--|--|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |  |  |  | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
|  |  |  |  | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
| Sheet 13 of 16   |  |  |  | APPLICANT: Krieg et al.     |                                   |
|  |  |  |  | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |      |  |  |
|---|------|--|--|
| * | C118 | Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.  |  |
| * | C119 | Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.  |  |
| * | C120 | Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.     |  |
| * | C121 | Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.                              |  |
| * | C122 | Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.                       |  |
| * | C123 | Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.                   |  |
| * | C124 | Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.    |  |
| * | C125 | Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.                                  |  |
| * | C126 | Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.   |  |
| * | C127 | Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.  |  |
| * | C128 | Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.                                 |  |
| * | C129 | Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.   |  |
| * | C130 | Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.                       |  |
| * | C131 | Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.                      |  |
| * | C132 | Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.            |  |
| * | C133 | Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004. |  |
| * | C134 | Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.                               |  |
| * | C135 | Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.                                      |  |
| * | C136 | Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.                             |  |
| * | C137 | Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.  |  |
| * | C138 | Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.  |  |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|   |    |    |    |                             |                                   |
|---|----|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)    |    |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT |    |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|   |    |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet   | 14 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |      |   |  |
|---|------|---|--|
| * | C139 | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.                          |  |
| * | C140 | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.                 |  |
| * | C141 | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.   |  |
| * | C142 | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.  |  |
| * | C143 | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.   |  |
| * | C144 | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.  |  |
| * | C145 | Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.                               |  |
| * | C146 | Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.                                 |  |
| * | C147 | Amended Claims for Application Number 09/265,191, filed March 10, 1999.   |  |
| * | C148 | Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.                         |  |
| * | C149 | Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004. |  |
| * | C150 | Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.   |  |
| * | C151 | Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.  |  |
| * | C152 | Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.   |  |
| * | C153 | Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.  |  |
| * | C154 | Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.                           |  |
| * | C155 | Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.                              |  |
| * | C156 | Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.                    |  |
| * | C157 | Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.  |  |
| * | C158 | Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.  |  |
| * | C159 | Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.  |  |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|  |    |    |    |                             |                                   |
|--|----|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |    |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
|  |    |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|  |    |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet  | 15 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|   |      |   |  |
|---|------|---|--|
| * | C160 | Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.                      |  |
| * | C161 | Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.                      |  |
| * | C162 | Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.                       |  |
| * | C163 | Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.          |  |
| * | C164 | Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.   |  |
| * | C165 | Patent Interference No. 105,171. Judgment and Order. March 10, 2005.  |  |
| * | C166 | Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.   |  |
| * | C167 | Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.   |  |
| * | C168 | Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.  |  |
| * | C169 | Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.  |  |
|   | C170 | Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on interference estoppel). (Electronically filed, unsigned).                                     |  |
|   | C171 | Patent Interference No. 105,526.. Krieg Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). June 18, 2007. |  |
|   | C172 | Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and 105). (Electronically filed, unsigned). July 25, 2007.                                   |  |
|   | C173 | Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). June 18, 2007.   |  |
|   | C174 | Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. § 112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.                |  |
|   | C175 | Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-Fact). (Electronically filed, unsigned). June 18, 2007.                                  |  |
|   | C176 | Patent Interference No. 105,526.. Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.               |  |
|   | C177 | Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.                    |  |
|   | C178 | Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz Parent Application) (Electronically filed, unsigned) July 25, 2007.                           |  |
|   | C179 | Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58) (Electronically filed, unsigned) July 25, 2007.   |  |
|   | C180 | Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement and Written Description) (Electronically filed, unsigned) September 10, 2007.          |  |
|   | C181 | Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007.  |  |
|   | C182 | Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed, unsiged) September 10, 2007.   |  |

EXAMINER:

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

|  |    |    |    |                             |                                   |
|--|----|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08)               |    |    |    | APPLICATION NO.: 10/817,165 | ATTY. DOCKET NO.: C1039.70048US02 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |    |    |    | FILING DATE: April 2, 2004  | CONFIRMATION NO.: 1597            |
|  |    |    |    | APPLICANT: Krieg et al.     |                                   |
| Sheet  | 16 | of | 16 | GROUP ART UNIT: 1645        | EXAMINER: Nita M. Minnifield      |

|  |      |   |  |
|--|------|---|--|
|  | C183 | Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims 46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007. |  |
|  | C184 | Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1) (Electronically filed, unsigned) September 10, 2007.  |  |
|  | C185 | Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2) (Electronically filed, unsigned) September 10, 2007.  |  |
|  | C186 | Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.                |  |
|  | C187 | Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007  |  |
|  | C188 | Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007  |  |
|  | C189 | Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007  |  |
|  | C190 | Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007  |  |
|  | C191 | Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007  |  |
|  | C192 | Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007  |  |
|  | C193 | Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007  |  |
|  | C194 | Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007  |  |

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818, 918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

|           |                  |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.